SCHEMBL24259025

SCHEMBL24259025

CC(O)CCCCc1nc(C2CC2)no1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
AKR1C4 P17516 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
HSD11B1 P28845 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 1/20 0.34
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
LDHA P00338 2/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
LMNA P02545 1/20 0.31
CNR2 P34972 1/20 0.31
CCR5 P51681 1/20 0.30
ALOX5AP P20292 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258804 0.78 AKR1C4 (0.44) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
SCHEMBL24452449 0.78 MAPT (0.38) L3MBTL1
SCHEMBL24259698 0.76 L3MBTL1 (0.41) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
SCHEMBL24258686 0.74 MIF (0.42) L3MBTL1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL24258740 0.74 L3MBTL1 (0.39) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
SCHEMBL24092039 0.73 POLB (0.40) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
SCHEMBL19745592 0.71 L3MBTL1 (0.43) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
Hydrochloric Acid SCHEMBL3948870 0.70 L3MBTL1 (0.43) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
SCHEMBL18507237 0.67 MEN1 (0.41) POLBL3MBTL1AKR1C4AKR1C3AKR1C2
SCHEMBL19002838 0.67 POLB (0.41) POLBL3MBTL1AKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-05-05 US disclosed
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS FXR1, NR1H4, FXR2 POLB 4337/4885L3MBTL1 4270/4885AKR1C4 502/4885
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 POLB 4337/4885L3MBTL1 4270/4885AKR1C4 502/4885
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 POLB 4337/4885L3MBTL1 4270/4885AKR1C4 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.